Discuss Cytokinetics Inc.
Cytokinetics Inc.
WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
47,40 €
0,85 %
Buy with target price 16.0
Sell with target price 16.0
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $58.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $56.00 to $48.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at Mizuho. They set a "buy" rating and a $80.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at HC Wainwright from $56.00 to $49.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at UBS Group AG from $67.00 to $61.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $60.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $58.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at HC Wainwright from $49.00 to $58.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $58.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at B. Riley. They set a "buy" rating and a $66.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at HC Wainwright from $58.00 to $94.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Needham & Company LLC from $60.00 to $108.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Truist Financial Co. from $60.00 to $86.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Neueste Beiträge
DA_Davidson in i3 Verticals diskutieren